Bladder cancer
cystoscopy
multiparametric cystoscopy (MP cystoscopy)
multispectral
photodynamic diagnostic (PDD)
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
02
11
2020
accepted:
04
04
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
ppublish
Résumé
Real-time multispectral imaging (rMSI) simultaneously provides white light (WL), photodynamic diagnosis (PDD) images, and a real-time fusion of both. It may improve the detection of bladder tumors. However, rMSI has not been used for transurethral biopsy or resection so far. The aim of this A 3D printed rigid bladder phantom was equipped with small and flat (5 mm × 1 mm) mock-bladder-tumors made of silicone and fluorescent Qdots655 (Thermo Fisher Scientific, Germany). Urologists (n=15) were asked to perform a rigid cystoscopy and biopsy of all identified lesions (n=6) using a prototype rMSI system and the Image1 S system (Karl Storz, Tuttlingen). Success rate and completion time were measured. The image quality of both systems and the usability of the rMSI system according to the system usability scale (SUS) were evaluated with a task-specific questionnaire. Tumor detection and biopsy rate were 100% (90/90) for the rMSI system and 98.9% (89/90) for the Image1 S system (P=0.3). The biopsy completion time did not differ significantly between the systems (P=0.48). Differentiation between healthy and suspect mucosa with the rMSI system was rated as comparable to the Image1 S system by 53% of surgeons and as better by 33% of the surgeons. The median SUS score for the rMSI system was 87.5%. Accurate transurethral biopsies are feasible with the rMSI system. Furthermore, the rMSI system has an excellent SUS. This study paves the way to the first in-human transurethral resections of bladder tumors (TUR-B) using rMSI technology.
Sections du résumé
BACKGROUND
BACKGROUND
Real-time multispectral imaging (rMSI) simultaneously provides white light (WL), photodynamic diagnosis (PDD) images, and a real-time fusion of both. It may improve the detection of bladder tumors. However, rMSI has not been used for transurethral biopsy or resection so far. The aim of this
METHODS
METHODS
A 3D printed rigid bladder phantom was equipped with small and flat (5 mm × 1 mm) mock-bladder-tumors made of silicone and fluorescent Qdots655 (Thermo Fisher Scientific, Germany). Urologists (n=15) were asked to perform a rigid cystoscopy and biopsy of all identified lesions (n=6) using a prototype rMSI system and the Image1 S system (Karl Storz, Tuttlingen). Success rate and completion time were measured. The image quality of both systems and the usability of the rMSI system according to the system usability scale (SUS) were evaluated with a task-specific questionnaire.
RESULTS
RESULTS
Tumor detection and biopsy rate were 100% (90/90) for the rMSI system and 98.9% (89/90) for the Image1 S system (P=0.3). The biopsy completion time did not differ significantly between the systems (P=0.48). Differentiation between healthy and suspect mucosa with the rMSI system was rated as comparable to the Image1 S system by 53% of surgeons and as better by 33% of the surgeons. The median SUS score for the rMSI system was 87.5%.
CONCLUSIONS
CONCLUSIONS
Accurate transurethral biopsies are feasible with the rMSI system. Furthermore, the rMSI system has an excellent SUS. This study paves the way to the first in-human transurethral resections of bladder tumors (TUR-B) using rMSI technology.
Identifiants
pubmed: 34295724
doi: 10.21037/tau-20-1372
pii: tau-10-06-2373
pmc: PMC8261439
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2373-2383Informations de copyright
2021 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1372). JR, GC, BG, CB and NCD report grants from the German Ministry for Education and Research (GO-Bio Project 031B0219). NCD is a co-inventor in a patent WO2015185661A1 family. NCD and BG are shareholders of technology start-up “Thericon GmbH” with the aim to commercialize multispectral imaging technology. The other authors have no conflicts of interest to declare.
Références
J Biophotonics. 2020 Feb;13(2):e201960025
pubmed: 31617683
Int J Technol Assess Health Care. 2011 Jan;27(1):3-10
pubmed: 21262078
Transl Androl Urol. 2021 Jan;10(1):1-6
pubmed: 33532288
Eur Urol. 2013 Oct;64(4):624-38
pubmed: 23906669
Curr Opin Urol. 2014 Sep;24(5):487-91
pubmed: 24887047
Arch Med Sci. 2019 Oct 07;16(4):863-870
pubmed: 32542089
J Endourol. 2009 Feb;23(2):197-201
pubmed: 19196063
Urologe A. 2019 Dec;58(12):1435-1442
pubmed: 31531693
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
J Endourol. 2021 Mar 9;:
pubmed: 33528308
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Opt Express. 2017 May 29;25(11):12812-12829
pubmed: 28786634
Urology. 2005 Dec;66(6 Suppl 1):90-107
pubmed: 16399418
BJU Int. 2010 Mar;105(6):789-94
pubmed: 19832725
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Urology. 2006 Sep;68(3):538-42
pubmed: 16979748
Cancer. 2002 Sep 15;95(6):1234-8
pubmed: 12216090
Eur Urol Focus. 2020 Jul 15;6(4):674-682
pubmed: 30910393
Sci Rep. 2018 Jan 18;8(1):1129
pubmed: 29348548
Urology. 2020 Aug;142:231-236
pubmed: 32389818
Eur Urol. 2016 Mar;69(3):438-47
pubmed: 26508308
Eur Urol. 2020 Feb;77(2):251-259
pubmed: 31563499
J Urol. 2012 Jul;188(1):58-62
pubmed: 22583635
Eur Urol. 2010 Apr;57(4):595-606
pubmed: 20004052
J Urol. 2017 Mar;197(3 Pt 1):548-558
pubmed: 27780784
World J Urol. 2017 May;35(5):745-752
pubmed: 27604374
Eur Urol. 2010 Apr;57(4):655-60
pubmed: 19819064
Opt Lett. 2003 Dec 15;28(24):2485-7
pubmed: 14690122